| 1RV1 | C:27-102; C:27-102; C:27-102 | CRYSTAL STRUCTURE OF HUMAN MDM2 WITH AN IMIDAZOLINE INHIBITOR |
| 1T4E | B:27-102; B:27-102 | STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH A BENZODIAZEPINE INHIBITOR |
| 1T4F | M:27-102 | STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH AN OPTIMIZED P53 PEPTIDE |
| 1YCR | A:27-102 | MDM2 BOUND TO THE TRANSACTIVATION DOMAIN OF P53 |
| 1Z1M | A:27-102 | NMR STRUCTURE OF UNLIGANDED MDM2 |
| 3JZK | A:27-102 | CRYSTAL STRUCTURE OF MDM2 WITH CHROMENOTRIAZOLOPYRIMIDINE 1 |
| 3JZR | A:27-102 | HUMAN MDM2 LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDI6W) |
| 3JZS | A:27-102 | HUMAN MDM2 LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDIQ) |
| 3LBL | E:27-102; E:27-102; E:27-102 | STRUCTURE OF HUMAN MDM2 PROTEIN IN COMPLEX WITH MI-63-ANALOG |
| 3LNJ | E:27-102; E:27-102; E:27-102 | CRYSTAL STRUCTURE OF HUMAN MDM2 IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-ALPHA) |
| 3LNZ | O:27-102; O:27-102; O:27-102; O:27-102; O:27-102; O:27-102; O:27-102; O:27-102 | CRYSTAL STRUCTURE OF HUMAN MDM2 WITH A 12-MER PEPTIDE INHIBITOR PMI (N8A MUTANT) |
| 2VYR | D:26-101; D:26-101; D:26-101; D:26-101 | STRUCTURE OF HUMAN MDM4 N-TERMINAL DOMAIN BOUND TO A SINGLE DOMAIN ANTIBODY |
| 3JZO | A:26-101 | HUMAN MDMX LIGANDED WITH A 12MER PEPTIDE (PDI) |
| 3JZP | A:26-101 | HUMAN MDMX LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDI6W) |
| 3JZQ | B:26-101; B:26-101 | HUMAN MDMX LIGANDED WITH A 12MER PEPTIDE INHIBITOR (PDIQ) |
)
)